Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
Among patients with atrial fibrillation who were at moderate-to-high risk for stroke, treatment with abelacimab resulted in markedly lower levels of free factor XI and fewer bleeding events than treatment with rivaroxaban. (Funded by Anthos Therapeutics; AZALEA-TIMI 71 ClinicalTrials.gov number, NCT04755283.).
Authors
- Julia Kuder (ORCID: https://orcid.org/0000-0002-7099-1538)
- Róbert Gábor Kiss (ORCID: https://orcid.org/0000-0003-0514-7530)
- Wojciech Wojakowski (ORCID: https://orcid.org/0000-0002-3681-5207)
- Erica L. Goodrich (ORCID: https://orcid.org/0000-0002-8541-264X)
- Marc S. Sabatine (ORCID: https://orcid.org/0000-0002-0691-3359)
- Robert P. Giugliano (ORCID: https://orcid.org/0000-0003-4110-7675)
- Boyoung Joung (ORCID: https://orcid.org/0000-0001-9036-7225)
- Daniel M. Bloomfield
- Siddharth M. Patel (ORCID: https://orcid.org/0000-0002-4637-4361)
- David A. Morrow (ORCID: https://orcid.org/0000-0002-9589-5382)
- Jindřich Špinar (ORCID: https://orcid.org/0000-0002-0515-1989)
- Bruce A. Hug (ORCID: https://orcid.org/0000-0003-1726-5198)
- Sanobar Parkar
- Jeffrey Ian Weitz (ORCID: https://orcid.org/0000-0002-1092-7550)
- Sabina A. Murphy (ORCID: https://orcid.org/0000-0002-8231-3611)
- Stephen D. Wiviott (ORCID: https://orcid.org/0000-0002-4922-9880)
- Shih-Ann Chen
- Christian T. Ruff
- Shaun G. Goodman
Institutions
- Thrombolysis in Myocardial Infarction Study Group (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1056/nejmoa2406674
- Citations
- 86
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 119.38
Funders
- Anthos Therapeutics